{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:18:39Z","timestamp":1785395919387,"version":"3.56.0"},"reference-count":34,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST-109-2811-B-002-581"],"award-info":[{"award-number":["MOST-109-2811-B-002-581"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The prevalence of non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver diseases worldwide. This study examined the potential protective effects of a naturally occurring polyphenolic compound, methyl brevifolincarboxylate (MBC) on fatty liver injury in vitro. The results showed that MBC at its non-cytotoxic concentrations, reduced lipid droplet accumulation and triglyceride (TG) levels in the oleic acid (OA)-treated human hepatocarcinoma cell line, SK-HEP-1 and murine primary hepatocytes. In OA-treated SK-HEP-1 cells and primary murine hepatocytes, MBC attenuated the mRNA expression levels of the de novo lipogenesis molecules, acetyl-coenzyme A carboxylase (Acc1), fatty acid synthase (Fasn) and sterol regulatory element binding protein 1c (Srebp1c). MBC promoted the lipid oxidation factor peroxisome proliferator activated receptor-\u03b1 (Ppar\u03b1), and its target genes, carnitine palmitoyl transferase 1 (Cpt1) and acyl-coenzyme A oxidase 1 (Acox1) in both the SK-HEP-1 cells and primary murine hepatocytes. The mRNA results were further supported by the attenuated protein expression of lipogenesis and lipid oxidation molecules in OA-treated SK-HEP-1 cells. The MBC increased the expression of AMP activated protein kinase (AMPK) phosphorylation. On the other hand, MBC treatment dampened the inflammatory mediator\u2019s, tumor necrosis factor (TNF)-\u03b1, interleukin-6 (IL-6), IL-8, and IL-1\u03b2 secretion, and nuclear factor (NF)-\u03baB expression (mRNA and protein) through reduced reactive oxygen species production in OA-treated SK-HEP-1 cells. Taken together, our results demonstrated that MBC possessed potential protective effects against NAFLD in vitro by amelioration of lipid metabolism and inflammatory markers through the AMPK\/NF-\u03baB signaling pathway.<\/jats:p>","DOI":"10.3390\/ijms221810062","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T21:23:29Z","timestamp":1631913809000},"page":"10062","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Methyl Brevifolincarboxylate Attenuates Free Fatty Acid-Induced Lipid Metabolism and Inflammation in Hepatocytes through AMPK\/NF-\u03baB Signaling Pathway"],"prefix":"10.3390","volume":"22","author":[{"given":"Madamanchi","family":"Geethangili","sequence":"first","affiliation":[{"name":"Department of Animal Science and Technology, National Taiwan University, Taipei 10672, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-Wei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Animal Science and Technology, National Taiwan University, Taipei 10672, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Mersmann","sequence":"additional","affiliation":[{"name":"Department of Animal Science and Technology, National Taiwan University, Taipei 10672, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9866-1776","authenticated-orcid":false,"given":"Shih-Torng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Animal Science and Technology, National Taiwan University, Taipei 10672, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Berardo, C., Di Pasqua, L.G., Cagna, M., Richelmi, P., Vairetti, M., and Ferrigno, A. (2020). Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: Current issues and future perspectives in preclinical and clinical research. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249646"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/etm.2020.9154","article-title":"Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease","volume":"20","author":"Shao","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lonardo, A., Leoni, S., Alswat, K.A., and Fouad, Y. (2020). History of nonalcoholic fatty liver disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165888"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"112311","DOI":"10.1016\/j.ejmech.2020.112311","article-title":"Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment","volume":"197","author":"Yang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/hep.31229","article-title":"Genetic pathways in nonalcoholic fatty liver disease: Insights from systems biology","volume":"72","author":"Sookoian","year":"2020","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"12279","DOI":"10.1074\/jbc.REV120.011356","article-title":"From over nutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases","volume":"295","author":"Zhao","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.12975","article-title":"Natural antioxidants for non-alcoholic fatty liver disease: Molecular targets and clinical perspectives","volume":"36","author":"Salomone","year":"2016","journal-title":"Liver Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jep.2007.11.040","article-title":"Anti-oxidant and inflammatory mediator\u2019s growth inhibitory effects of compounds isolated from Phyllanthus urinaria","volume":"116","author":"Fang","year":"2008","journal-title":"J. Ethnopharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1248\/bpb.30.382","article-title":"Inhibitory effects of methyl brevifolincarboxylate isolated from Phyllanthus niruri L. on platelet aggregation","volume":"30","author":"Iizuka","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"ref_11","first-page":"389","article-title":"Human DNA topoisomerase inhibitors from Potentilla argentea and their cytotoxic effect against MCF-7","volume":"63","author":"Tomczyk","year":"2008","journal-title":"Pharmazie"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8740","DOI":"10.3390\/ijms12128740","article-title":"Chromatographic fingerprint and the simultaneous determination of five bioactive components of Geranium carolinianum L. water extract by high performance liquid chromatography","volume":"12","author":"Wu","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/cbdd.13740","article-title":"Methyl brevifolincarboxylate, a novel influenza virus PB2 inhibitor from Canarium album (Lour.) Raeusch","volume":"96","author":"Chen","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/1389450120666191007111712","article-title":"Natural aldose reductase inhibitor: A potential therapeutic agent for non-alcoholic fatty liver disease","volume":"21","author":"Qiu","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Abbate, J.M., Macr\u00ec, F., Capparucci, F., Iaria, C., Briguglio, G., Cicero, L., Salvo, A., Arfuso, F., Ieni, A., and Piccione, G. (2020). Administration of protein hydrolysates from anchovy (Engraulis encrasicolus) waste for twelve weeks decreases metabolic dysfunction-associated fatty liver disease severity in ApoE\u2212\/\u2212Mice. Animals, 10.","DOI":"10.3390\/ani10122303"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3389\/fphar.2018.01109","article-title":"A review of the phytochemistry and pharmacology of Phyllanthus urinaria L.","volume":"9","author":"Geethangili","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.22039","article-title":"Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo","volume":"47","author":"Shen","year":"2008","journal-title":"Hepatology"},{"key":"ref_18","first-page":"1635837","article-title":"Compound Phyllanthus urinaria L inhibits HBV-related HCC through HBx-SHH pathway axis inactivation","volume":"2019","author":"Li","year":"2019","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101143","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107401","DOI":"10.1016\/j.pharmthera.2019.107401","article-title":"The unfolded protein response and hepatic lipid metabolism in non-alcoholic fatty liver disease","volume":"203","author":"Song","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14656566.2020.1744564","article-title":"Current and new pharmacotherapy options for non-alcoholic steatohepatitis","volume":"21","author":"Sumida","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.14272","article-title":"Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: Results from two early phase randomized trials","volume":"23","author":"Beysen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: The role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Siddiqui, M.S., Idowu, M.O., Parmar, D., Borg, B.B., Denham, D., Loo, N.M., Lazas, D., Younes, Z., and Sanyal, A.J. (2020). A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol.","DOI":"10.1016\/j.cgh.2020.10.051"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Salomone, F., Barbagallo, I., Godos, J., Lembo, V., Currenti, W., Cin\u00e0, D., Avola, R., D\u2019Orazio, N., Morisco, F., and Galvano, F. (2017). Silibinin restores NAD+ levels and induces the SIRT1\/AMPK pathway in non-alcoholic fatty liver. Nutrients, 9.","DOI":"10.3390\/nu9101086"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5763602","DOI":"10.1155\/2019\/5763602","article-title":"Recent advances in the pharmacological activities of dioscin","volume":"2019","author":"Yang","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liou, C.J., Lee, Y.K., Ting, N.C., Chen, Y.L., Shen, S.C., Wu, S.J., and Huang, W.C. (2019). Protective effects of licochalcone A ameliorates obesity and non-alcoholic fatty liver disease via promotion of the Sirt-1\/AMPK pathway in mice fed a high-fat diet. Cells, 8.","DOI":"10.3390\/cells8050447"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"106208","DOI":"10.1016\/j.intimp.2020.106208","article-title":"Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice","volume":"80","author":"Liu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/bph.14938","article-title":"Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3\/NF-\u03baB pathway in mice","volume":"177","author":"Wang","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1600632","DOI":"10.1002\/mnfr.201600632","article-title":"Chicoric acid attenuate a nonalcoholic steatohepatitis by inhibiting key regulators of lipid metabolism, fibrosis, oxidation, and inflammation in mice with methionine and choline deficiency","volume":"61","author":"Kim","year":"2017","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2174\/1389200221666200103090757","article-title":"Metabolism and pharmacokinetics of phytochemicals in the human body","volume":"20","author":"Rathaur","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e2000619","DOI":"10.1002\/mnfr.202000619","article-title":"Human gut microbiota metabolism of dietary sesquiterpene lactones: Untargeted metabolomics study of lactucopicrin and lactucin conversion in vitro and in vivo","volume":"64","author":"Garcia","year":"2020","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Schultz Moreira, A.R., R\u00fcschenbaum, S., Schefczyk, S., Hendgen-Cotta, U., Rassaf, T., Broering, R., Hardtke-Wolenski, M., and Buitrago-Molina, L.E. (2020). 9-PAHSA prevents mitochondrial dysfunction and increases the viability of steatotic hepatocytes. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218279"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/18\/10062\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:01:28Z","timestamp":1760166088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/18\/10062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":34,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["ijms221810062"],"URL":"https:\/\/doi.org\/10.3390\/ijms221810062","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]}}}